Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-Gastric/Gastroesophageal Junction Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT06364410
What this trial is testing

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Who this might be right for
Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+10 more
National Cancer Institute (NCI) 48
Not applicableUnknownNCT05649163
What this trial is testing

Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy

Who this might be right for
HER2Advanced Gastric CancerAdvanced Gastroesophageal Junction Adenocarcinoma+1 more
Shen Lin 306
Not applicableLooking for participantsNCT07464470
What this trial is testing

Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers

Who this might be right for
Gastric CancerEsophageal CancerBrain Metastases
Blokhin's Russian Cancer Research Center 30
Large-scale testing (Phase 3)Looking for participantsNCT06123494
What this trial is testing

SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen

Who this might be right for
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Jiangsu HengRui Medicine Co., Ltd. 360
Not applicableActive Not RecruitingNCT05165264
What this trial is testing

Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer

Who this might be right for
Gastric Cancer
Bristol-Myers Squibb 600
Large-scale testing (Phase 3)UnknownNCT02934464
What this trial is testing

Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers

Who this might be right for
Stomach Neoplasms
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 280
Testing effectiveness (Phase 2)Ended earlyNCT04604132
What this trial is testing

Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma

Who this might be right for
Gastric Adenocarcinoma
Basilea Pharmaceutica 47
Large-scale testing (Phase 3)Looking for participantsNCT06731478
What this trial is testing

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Gastric CancerGastroesophageal Junction Cancer
Daiichi Sankyo 726
Not applicableActive Not RecruitingNCT05993234
What this trial is testing

Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

Who this might be right for
HER2-positive Advanced Gastric CancerHER2-positive Gastroesophageal Junction Adenocarcinoma
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company 257
Large-scale testing (Phase 3)Looking for participantsNCT05677490
What this trial is testing

MFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Who this might be right for
Advanced Esophageal AdenocarcinomaAdvanced Gastric AdenocarcinomaAdvanced Gastroesophageal Junction Adenocarcinoma+12 more
Alliance for Clinical Trials in Oncology 382
Not applicableNot Yet RecruitingNCT07780968
What this trial is testing

Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA

Who this might be right for
Esophageal CancerGastroEsophageal CancerGastroesophageal-junction Cancer+2 more
Jazz Pharmaceuticals 300
Not applicableStudy completedNCT01220934
What this trial is testing

An Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 443
Early research (Phase 1)Ended earlyNCT04665921
What this trial is testing

SGN-STNV in Advanced Solid Tumors

Who this might be right for
Carcinoma, Non-Small Cell LungHER2 Negative Breast NeoplasmsOvarian Neoplasms+9 more
Seagen Inc. 111
Testing effectiveness (Phase 2)Looking for participantsNCT05671822
What this trial is testing

Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer

Who this might be right for
HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 258
Early research (Phase 1)Looking for participantsNCT06773312
What this trial is testing

BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.

Who this might be right for
Advanced or Metastatic Gastric CancerGastroesophageal Junction Adenocarcinoma
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. 80
Testing effectiveness (Phase 2)Study completedNCT04309578
What this trial is testing

Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC

Who this might be right for
Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma
Asan Medical Center 28
Testing effectiveness (Phase 2)Study completedNCT03329690
What this trial is testing

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

Who this might be right for
Neoplasm, Gastrointestinal
Daiichi Sankyo Co., Ltd. 233
Testing effectiveness (Phase 2)Looking for participantsNCT07334431
What this trial is testing

Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer

Who this might be right for
Gastric AdenocarcinomaGastric (Stomach) CancerGEJ Adenocarcinoma+3 more
Henan Cancer Hospital 45
Not applicableAvailableNCT06048081
What this trial is testing

Early Access Program for Zolbetuximab

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma CancerLocally Advanced Unresectable Gastric Adenocarcinoma CancerMetastatic Gastric Adenocarcinoma Cancer+1 more
Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Active Not RecruitingNCT06157892
What this trial is testing

Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Who this might be right for
Breast NeoplasmsGastroesophageal Junction AdenocarcinomaHER2 Low Breast Neoplasms+7 more
Seagen, a wholly owned subsidiary of Pfizer 54
Next Page